Why Neil Woodford Has Sold Smith & Nephew Plc But Bought More Centrica Plc And SSE Plc

Dave Sullivan reviews some of the recent contrarian trades made by Neil Woodford’s equity income fund: Smith & Nephew plc (LON: SN), Centrica plc (LON: CNA) and SSE plc (LON: SSE).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the recently released February Fund round-up of Neil Woodford’s equity income fund, there were a few transactions that stood out to me as being rather contrarian.

Selling Out Of The Takeover Target

The fund has now disposed of its entire position in Smith & Nephew (LSE: SN).  Mr Woodford acknowledged that a bid for the company may well lead to a considerable appreciation in the share price.  However, with the share price at an all-time high, he felt that there were better opportunities elsewhere.  It is true that the company trades on a fairly lofty forward multiple of around 19 times earnings and expects to yield less than 2%.  It is also possible that the deal was sealed when Stryker, the US healthcare company, announced a $2 billion share buyback last week, finally quashing hopes that a bid was about to be announced.

Topping Up On The Unloved

In contrast, Mr Woodford seems to have seen an opportunity following the share price weakness of both Centrica (LSE: CNA) and SSE (LSE: SSE).

Centrica was the largest detractor to the funds performance in February, after the company cut its dividend with its full-year results.  Mr Woodford didn’t feel that the dividend cut was necessary but this may have simply be down to the new chief executive, Ian Conn, taking the opportunity to get any bad news out of the way early in his tenure rather than risk a credit downgrade.  It is fair to say that a dividend cut was already largely reflected in the share price. Centrica was hit by a combination of factors recently:

  • US and UK weather conditions;
  • The oil price collapse;
  • Political and regulatory pressure.

However, he felt that these issues will abate and its long-term valuation attractions will become much more apparent.  He topped up on both Centrica and SSE, which was weak in sympathy.

Whilst we will have to wait until May for SSE’s full-year results and its final dividend, it did release a third-quarter trading update on 26th January.  It stated that:

  • SSE still expects to report an increase in the full-year dividend for 2014/15 that will at least be equal to RPI inflation;
  • Confirms that SSE is targeting an increase in the full-year dividend for 2015/16 of at least RPI inflation, with annual increases thereafter of at least RPI inflation also being targeted.

Where Does That Leave Us Investors?

With no dividend cut, SSE still yields over 6% but with RPI currently at just over 1% I wouldn’t expect outsized increases, either.  Whilst Centrica has bitten the bullet by re-basing its dividend, this will assist in reducing its debt and maintain capital expenditure — in the long run, it may be seen as a smart move… as may Neil Woodford’s top-ups.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dave Sullivan has no position in any shares mentioned. The Motley Fool UK has recommended Centrica. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »

Investing Articles

Why I’ve just sold two of the largest investments in my Stocks and Shares ISA

Stephen Wright has been making room for a new addition to his Stocks and Shares ISA. What is it and…

Read more »

Investing Articles

2 UK shares I’m avoiding like the plague in today’s stock market

Stephen Wright is a big fan of UK shares. But both the FTSE 100 and the FTSE 250 contain companies…

Read more »